弘和仁爱医疗公告，公司间接非全资附属公司买方与卖方订立股权转让协议，收购慈溪弘和物业管理有 限公司全部股权，代价为人民币4947万元。该代价将分三期支付。收购事项完成后，目标公司将成为弘 和仁爱医疗的附属公司，其财务业绩将并入集团综合财务报表。由于有关收购事项的最高适用百分比率 超过5%但低于25%，因此收购事项构成本公司之须予披露交易，并须遵守上市规则第十四章项下之申 报及公告规定。 ...

弘和仁愛醫療集團有限公司 Hospital Corporation of China Limited 股份代號 : 3869 2024 ANNUAL 2024 年報 REPORT 弘和仁愛醫療集團有限公司 Hospital Corporation of China Limited (Incorporated in the Cayman Islands with limited liability) Stock code: 3869 ANNUAL R E P O RT 20 2 4 年 報 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務概要 | | 5 | 行政總裁報告 | | 7 | 管理層討論及分析 | | 21 | 董事會報告 | | 59 | 董事及高級管理層履歷 | | 68 | 企業管治報告 | | 83 | 獨立核數師報告 | | 89 | 綜合損益表 | | 90 | 綜合損益及其他全面收益表 | | 91 | 綜合財務狀況表 | | 93 | 綜合權益變動表 | | 94 | 綜合現金流量表 | | 95 | 綜合財務報表附註 | 公司資料 董事會 執行董事 陳帥 ...

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 1,442,292,000, representing a slight increase from RMB 1,427,733,000 in 2023, which is a growth of approximately 1.0%[5] - The gross profit margin improved to 19.1% in 2024 from 16.8% in 2023, while the adjusted gross profit margin increased to 20.3% from 18.3%[5] - The net profit for the year was RMB 13,790,000, a significant decrease from RMB 168,344,000 in the previous year, indicating a decline of approximately 91.8%[6] - Adjusted net profit for the year was RMB 141,924,000, up from RMB 104,120,000 in 2023, reflecting an increase of about 36.5%[5] - Basic earnings per share turned negative at RMB (0.282) compared to RMB 0.956 in 2023, indicating a substantial decline in profitability[6] - The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for 2024 was RMB 258,091 thousand, compared to RMB 208,749 thousand in 2023, indicating a growth of about 23.7%[27][28] - The net loss attributable to the company's owners for 2024 was RMB 38,628 thousand, a significant decline from a profit of RMB 131,384 thousand in 2023[35] - Revenue increased by approximately 1.0% from RMB 1,427.7 million in 2023 to RMB 1,442.3 million in 2024[52] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 1,099,116,000, compared to RMB 950,309,000 in 2023, marking an increase of approximately 15.6%[8] - The total assets of the group as of December 31, 2024, were RMB 2,583,162 thousand, up from RMB 2,498,100 thousand in 2023, reflecting an increase of approximately 3.4%[27][28] - The total liabilities increased to RMB 2,007,483 thousand in 2024 from RMB 1,906,897 thousand in 2023, marking an increase of about 5.3%[27][28] - Non-current liabilities decreased to RMB 196,614,000 from RMB 244,338,000 in 2023, a reduction of approximately 19.5%[9] - The company’s total equity decreased to RMB 575,679,000 from RMB 591,203,000, reflecting a decline of about 2.6%[9] - As of December 31, 2024, the group's current liabilities exceed current assets by RMB 711,753,000, including convertible bonds maturing in 2025 amounting to RMB 1,060,315,000[14] - The adoption of the revised International Accounting Standard 1 resulted in the reclassification of convertible bonds maturing on September 30, 2025, from non-current to current liabilities, impacting the total current liabilities to RMB 1,662,559,000[19] Cash Flow and Financial Position - The company reported a cash and cash equivalents balance of RMB 714,120,000, up from RMB 523,027,000 in the previous year, representing a growth of about 36.5%[8] - The net cash inflow from operating activities was approximately RMB 212.1 million, including a net cash inflow of RMB 243.6 million before changes in working capital[69] - The company reported a net cash inflow from investment activities of approximately RMB 42.6 million, primarily from the redemption of fixed deposits and the sale of financial assets[70] - As of December 31, 2024, cash and cash equivalents amounted to approximately RMB 714.1 million, compared to RMB 523.0 million in 2023[71] - The company's interest-bearing debt ratio was approximately 3.2% as of December 31, 2024[71] Revenue Segmentation - The group operates through three reportable segments: Integrated Hospital Services, Hospital Management Services, and Pharmaceutical Sales, with revenues generated from outpatient and inpatient services, management services, and retail pharmacy sales respectively[20][21][22] - Hospital management services revenue rose by approximately 42.7% from RMB 86.9 million in 2023 to RMB 124.1 million in 2024[53] - Comprehensive hospital services revenue decreased by approximately 1.7% from RMB 1,326.3 million in 2023 to RMB 1,303.4 million in 2024[54] - Pharmaceutical sales revenue decreased from approximately RMB 11.5 million in 2023 to RMB 9.0 million in 2024, a decline of RMB 2.5 million[55] - The group reported external customer revenue of RMB 1,442,292 thousand in 2024, with the hospital services segment contributing RMB 1,303,405 thousand[27] Operational Highlights - The company is primarily engaged in operating and managing hospitals, providing management and supply chain services, and pharmaceutical sales in China[10] - The company is focusing on enhancing healthcare service quality and exploring systematic management solutions for non-public comprehensive medical institutions, leveraging digital technology[47] - The group has implemented a centralized procurement management system, organizing 22 significant procurement projects in 2024, including 13 medical device projects[49] - The company emphasizes a management philosophy of "lawful practice, safety standards, and healthy development," guiding hospitals in strategic planning and safety inspections[50] - The healthcare market is expected to face intensified competition in 2024, with policies aimed at improving medical service quality and efficiency[46] - The company is investing in digital health management capabilities, achieving recognition for its applications in AI-assisted imaging and smart case management[48] Employee and Governance - The total employee benefits expenditure, including director remuneration, was approximately RMB 446.7 million for the year ending December 31, 2024, compared to approximately RMB 430.5 million in 2023[84] - The workforce increased to 1,841 employees as of December 31, 2024, up from 1,457 employees in 2023, primarily due to business expansion[84] - The company has adopted the Corporate Governance Code and believes it has complied with applicable provisions during the review year[87] - The audit committee, consisting of three independent non-executive directors, has reviewed the financial statements for the fiscal year ending December 31, 2024, ensuring compliance with applicable accounting standards and regulations[89] Dividends and Investments - The company did not declare any dividends for the year ending December 31, 2024, consistent with 2023[43] - The company has not conducted any significant acquisitions or disposals of subsidiaries, associates, or joint ventures from January 1, 2024, to December 31, 2024[79] - There are no major investments or future plans for significant investments or capital assets as of December 31, 2024[80] - The company does not recommend the payment of a final dividend for the year ending December 31, 2024[83] Risks and Compliance - The company has faced foreign exchange risks primarily related to transactions in USD and HKD, with no hedging instruments currently in use[81] - The company has adopted a code of conduct for securities trading by directors and relevant employees, confirming compliance for the fiscal year ending December 31, 2024[88]

Revenue and Profitability - Revenue for the six months ended June 30, 2024, was RMB 719.5 million, a slight increase from RMB 717.8 million in the same period of 2023[6]. - Adjusted gross profit for the period was RMB 161.8 million, with an adjusted gross profit margin of 22.5%, up from 18.3% in the previous year[6]. - Adjusted net profit reached RMB 87.3 million, representing an increase from RMB 60.9 million in the prior year, with an adjusted net profit margin of 12.1% compared to 8.5%[6]. - The hospital management services segment generated revenue of RMB 62.0 million, significantly up from RMB 36.9 million in the previous year[6]. - The integrated hospital services segment reported revenue of RMB 651.7 million, a decrease from RMB 674.2 million year-on-year[6]. - The company's revenue for the period was approximately RMB 719.5 million, a 0.2% increase from RMB 717.8 million in the same period last year, primarily due to increased management service income provided to hospitals[14]. - Adjusted gross profit was approximately RMB 161.8 million, a 23.0% increase from RMB 131.6 million in the same period last year, driven by increased diagnostic service income from Yangsi Hospital and reduced related costs[14]. - Adjusted operating profit was approximately RMB 123.0 million, up from RMB 83.6 million in the same period last year, mainly due to increased diagnostic service income from Yangsi Hospital and government subsidies[15]. - Adjusted net profit was approximately RMB 87.3 million, a 43.4% increase from RMB 60.9 million in the same period last year, attributed to increased diagnostic service income and government subsidies[15]. Financial Position - As of June 30, 2024, total equity was approximately RMB 612.5 million, up from RMB 591.2 million as of December 31, 2023[16]. - Current assets increased to approximately RMB 959.5 million from RMB 950.3 million as of December 31, 2023, mainly due to increases in cash and cash equivalents and receivables[16]. - Current liabilities decreased to approximately RMB 1,628.9 million from RMB 1,662.6 million as of December 31, 2023, primarily due to reductions in accrued expenses and other payables[16]. - The company maintained a current ratio of approximately 0.59 as of June 30, 2024, compared to 0.57 as of December 31, 2023[16]. - The company has a debt-to-asset ratio of approximately 3.3% as of June 30, 2024, indicating sufficient operational funding to meet demands[17]. - The company reported a total asset value of RMB 2,493,617 thousand as of June 30, 2024, with total liabilities amounting to RMB 1,881,144 thousand[84]. - The company’s total liabilities exceeded its total assets by RMB 669,409,000 as of June 30, 2024, indicating potential liquidity concerns[72]. Operational Initiatives - The company is enhancing standardized management solutions for its healthcare institutions to improve operational quality and asset value[9]. - The group is actively implementing quality and service improvement initiatives across its healthcare network, focusing on training and risk management[10]. - The company has established a dedicated internal control department to oversee auditing and risk management, aiming to identify and mitigate key risks[10]. - The company continues to deepen anti-corruption measures and compliance management within its healthcare network[10]. Employee and Shareholder Information - As of June 30, 2024, the company had a total of 1,491 employees, an increase from 1,437 employees as of June 30, 2023[27]. - Employee benefits expenses, including director remuneration, amounted to approximately RMB 215.1 million for the six months ended June 30, 2024, compared to RMB 209.3 million for the same period in 2023[27]. - Liu Lu holds a 6.58% equity interest in the company, representing 9,098,800 shares as of June 30, 2024[29]. - Hony Group Management Limited and its affiliates collectively hold approximately 117.01% equity interest in the company, with 161,693,985 shares[30]. - Hony Fund V, L.P. and its affiliates also hold 123,000,000 shares, representing 89.01% equity interest[30]. - The company has adopted several share-based payment plans to incentivize and reward outstanding contributors[27]. Debt and Financing - The company has entered into a loan agreement with Jinhua Hospital, with a maximum principal amount of RMB 100.0 million and an annual interest rate of 4.79%[19]. - As of June 30, 2024, the outstanding principal amount of the existing loan is RMB 20.0 million[19]. - The maturity date of the convertible bonds issued to Yu Feng Limited has been extended from December 29, 2023, to September 30, 2025[22]. - The company has issued convertible bonds amounting to HKD 468.0 million, with an initial conversion price of HKD 18.00 per share[35]. - The net proceeds from the convertible bonds issuance were approximately HKD 467.0 million, with HKD 405.0 million used for the acquisition of Cixi Hongai Medical Management Co., Ltd.[36]. - The company has not converted any of the convertible bonds into shares as of June 30, 2024[36]. Compliance and Governance - The audit committee has reviewed the unaudited interim results and financial information, confirming compliance with applicable accounting standards and regulations[59]. - The company has adopted a code of conduct for securities trading, ensuring compliance by all directors and relevant employees during the reporting period[58]. - The company is currently seeking a suitable candidate for the position of CEO to ensure compliance with corporate governance codes[57]. Segment Performance - The group reported three operating segments: Comprehensive Hospital Services, Hospital Management Services, and Pharmaceutical Sales, all generating revenue in China[79][80][81]. - The revenue from the Comprehensive Hospital Services segment is derived from outpatient and inpatient services provided in hospitals[80]. - The Hospital Management Services segment generates income from operational management, supply chain services, and other ancillary services[81]. - The Pharmaceutical Sales segment primarily comes from retail pharmacy sales[82]. - The segment profit before interest, tax, depreciation, and amortization (EBITDA) for the integrated hospital services was RMB 73,841 thousand, while the hospital management services segment reported RMB 79,819 thousand[84]. Financial Challenges - The company reported a loss attributable to shareholders of approximately RMB 18.7 million for the six months ended June 30, 2024, resulting in a basic and diluted loss per share of RMB 0.14[37]. - The company incurred a net loss of RMB 18,718,000 for the six months ended June 30, 2024, compared to a profit of RMB 126,218,000 in the previous period[67]. - The company’s accumulated losses as of June 30, 2024, stood at RMB 943,009,000, reflecting ongoing financial challenges[67]. - The company reported a significant drop in financial income, with net financial income decreasing to RMB (52,360) thousand from RMB 128,794 thousand in the previous year[62]. Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2024, was RMB 54,982,000, compared to RMB 59,512,000 for the same period in 2023, reflecting a decline of approximately 4.5%[68]. - The company reported a net cash outflow from investing activities of RMB 5,458,000 for the six months ended June 30, 2024, significantly lower than RMB 63,402,000 in the prior year[68]. - The group acquired property and equipment valued at RMB 10,900,000 for the six months ending June 30, 2024, compared to RMB 3,041,000 for the same period in 2023, indicating a substantial increase in capital expenditure[100].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 719,503,000, a slight increase from RMB 717,831,000 in the same period last year, representing a growth of 0.2%[2] - Adjusted gross profit for the period was RMB 161,804,000, up from RMB 131,568,000, resulting in an adjusted gross margin of 22.5%, compared to 18.3% in the previous year[2] - Adjusted net profit increased to RMB 87,334,000, compared to RMB 60,893,000 in the prior period, reflecting a growth of 43.3%[2] - The company reported a net profit of RMB 25,497,000 for the current period, a significant decrease from RMB 177,916,000 in the previous year[3] - The basic earnings per share for the current period was (RMB 0.14), compared to RMB 0.91 in the same period last year[5] - The total comprehensive income for the period was RMB 21,270,000, down from RMB 185,274,000 in the previous year[6] - The company reported a net loss attributable to shareholders of RMB 18,718,000 for the six months ended June 30, 2024, compared to a profit of RMB 126,218,000 for the same period in 2023, marking a substantial decline in profitability[27] - The basic loss per share for the six months ended June 30, 2024, was RMB (0.14), compared to earnings of RMB 0.91 per share for the same period in 2023, indicating a significant downturn in earnings per share[27] Assets and Liabilities - Non-current assets totaled RMB 1,534,101,000 as of June 30, 2024, slightly down from RMB 1,547,791,000 at the end of 2023[7] - Current assets increased to RMB 959,516,000 from RMB 950,309,000 at the end of 2023[8] - The company’s total liabilities decreased to RMB 1,628,925,000 from RMB 1,662,559,000 at the end of 2023[8] - The net asset value increased to RMB 612,473,000 as of June 30, 2024, compared to RMB 591,203,000 at the end of 2023[8] - As of June 30, 2024, the group's current liabilities exceeded current assets by RMB 669,409,000, including RMB 989,673,000 of convertible bonds reclassified from non-current to current[10] - The total current liabilities amounted to RMB 1,628,925,000, reflecting a decrease of RMB 989,673,000 due to the reclassification of convertible bonds[13] - The total non-current liabilities amounted to RMB 252,219,000 after the reclassification of convertible bonds[13] - The company’s total liabilities as of June 30, 2024, were RMB 1,881,144,000, compared to RMB 1,906,897,000 as of December 31, 2023, showing a slight reduction in liabilities[20] Operational Segments - The group operates in three reportable segments: Comprehensive Hospital Services, Hospital Management Services, and Pharmaceutical Sales, all generating revenue in China[15] - For the six months ended June 30, 2024, the total revenue from the pharmaceutical sales segment was RMB 4,427,000, a decrease from RMB 6,787,000 for the same period in 2023, representing a decline of approximately 34.5%[19] - The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the pharmaceutical sales segment was RMB 498,000 for the six months ended June 30, 2024, compared to RMB 533,000 for the same period in 2023, indicating a slight decrease of about 6.6%[20] - The total assets for the pharmaceutical sales segment as of June 30, 2024, were RMB 6,408,000, while total liabilities were RMB 2,817,000, reflecting a significant asset-to-liability ratio[19] Government Grants and Taxation - The company recognized government grants and subsidies amounting to RMB 10,179,000 for the six months ended June 30, 2024, compared to no such income in the same period of 2023[22] - The income tax expense for the six months ended June 30, 2024, was RMB 35,948,000, an increase from RMB 23,056,000 for the same period in 2023, reflecting a rise of approximately 56%[21] Employee and Governance - The total employee benefits expenditure, including director remuneration, for the six months ended June 30, 2024, is approximately RMB 2,151 million, compared to RMB 2,093 million for the same period in 2023, reflecting an increase of 2.8%[49] - As of June 30, 2024, the company has a total of 1,491 employees, an increase from 1,437 employees as of June 30, 2023, representing a growth of 3.8%[49] - The audit committee has reviewed the unaudited performance and interim financial information, confirming compliance with applicable accounting standards and regulations[52] - The company has adopted the corporate governance code as per the listing rules and is currently seeking a suitable candidate for the CEO position to ensure compliance with governance standards[51] Future Outlook and Strategic Initiatives - The outlook for the second half of 2024 includes a commitment to strengthen control systems and improve asset quality while adapting to national healthcare reform requirements[37] - The company is actively addressing challenges posed by domestic policy and industry changes to ensure the sustainable operation of its network hospitals[34] - The group continues to focus on expanding its hospital management and consulting services in the Chinese market[15] - The company is focusing on enhancing the quality and safety of medical services through systematic training and quality improvement initiatives in its network hospitals[35] - The group is advancing the construction of a centralized procurement platform to reduce costs and improve supply chain efficiency for medical supplies[36] Dividends and Investments - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the previous year[33] - The company did not engage in any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the period from January 1, 2024, to June 30, 2024[41] - There were no major investments or future plans for significant investments or capital assets as of June 30, 2024[44] Risks and Compliance - The company faces foreign exchange risks primarily related to transactions in USD and HKD, but does not currently use any derivative financial instruments to hedge these risks[45] - The company has not experienced any significant events after June 30, 2024, up to the date of this announcement[50] - There have been no purchases, sales, or redemptions of the company's listed securities by the company or its subsidiaries[53] - The interim report will be published on the Hong Kong Stock Exchange and the company's website at an appropriate time[54]

有關進一步詳情，請參閱本公司日期為二零二三年六月六日及二零二三年七月 三十一日的公告以及本公司日期為二零二三年七月七日的通函。 提前贖回立濤可換股債券後，將不會有任何立濤可換股債券的本金金額未償還，且 概無立濤可換股債券已經或將被轉換為股份。 有關詳情，請參閱本公司日期為二零二一年八月十二日、二零二一年十月八日、二 零二一年十月十五日及二零二三年七月三十一日的公告以及本公司日期為二零 二一年九月十六日的通函。 於二零一九年七月二十四日，本公司與金華廣福醫院訂立貸款協議（「現有二零 一九年貸款協議」），據此，本公司已有條件同意向金華廣福醫院授出本金額為人 民幣80百萬元，年利率為5.23%（根據中國人民銀行不時公佈的適用基準利率進行 調整），期限自有關提款日期起計36個月的貸款（「現有二零一九年貸款」）。於二零 二三年十二月三十一日，金華廣福醫院已悉數提取現有二零一九年貸款，而現有二 零一九年貸款的未償還本金額為人民幣80百萬元。 考慮到本公司的現金管理需求，於二零二三年十一月三日，西藏弘和志遠與金華廣 福醫院訂立補充協議（「二零二三年貸款補充協議」），據此，西藏弘和志遠授予金 華廣福醫院的循環貸款信貸限額由人 ...

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,427,733 thousand, representing a 24.9% increase from RMB 1,142,951 thousand in 2022[6] - The net profit for the year was RMB 168,344 thousand, a significant recovery from a loss of RMB 528,597 thousand in the previous year[6] - Adjusted net profit increased to RMB 104,120 thousand, compared to RMB 65,858 thousand in 2022, reflecting a 58% year-over-year growth[6] - Basic earnings per share improved to RMB 0.956 from a loss of RMB 3.480 in 2022[6] - The company reported a total comprehensive income of RMB 181,528 thousand for the year, recovering from a loss of RMB 531,378 thousand in 2022[22] - The profit before tax for 2023 was RMB 216,204 thousand, compared to a loss of RMB 316,837 thousand in 2022, indicating a turnaround in profitability[75][83] - The company reported a pre-tax profit of RMB 72,345 thousand, a significant improvement compared to a loss of RMB 458,611 thousand in the previous year[102] - The company recorded a net profit of approximately RMB 168.3 million for the year ended December 31, 2023, a significant increase of approximately RMB 696.9 million compared to a net loss of RMB 528.6 million in 2022[185] Revenue Breakdown - The company’s external customer revenue for comprehensive medical services was RMB 1,326,280 thousand in 2023, up from RMB 1,049,374 thousand in 2022, marking a growth of approximately 26.38%[80] - Revenue from external customers reached RMB 1,142,951 thousand, an increase from RMB 1,049,374 thousand in the previous year[100] - Hospital management services revenue increased by approximately 6.5% to RMB 86.9 million from RMB 81.6 million in 2022, primarily due to increased income from hospital management and supply chain services[178] - Pharmaceutical sales revenue rose to approximately RMB 11.5 million from RMB 11.1 million in 2022, driven by increased supply income from Jinhua Pharmaceutical[179] - Revenue from the hospital management services segment rose by approximately 26.4% from RMB 1,049.4 million in 2022 to about RMB 1,326.3 million in 2023, primarily due to increased outpatient and inpatient volumes[198] Cost and Expenses - Costs increased by approximately 19.8% from about RMB 992.1 million in 2022 to about RMB 1,188.4 million in 2023, mainly due to higher inventory-related costs[199] - Administrative expenses rose by approximately 35.8% from about RMB 95.2 million in 2022 to about RMB 129.2 million in 2023, driven by increased employee benefits and technology operation costs[200] Asset and Liability Management - Non-current assets decreased slightly to RMB 1,378,847 thousand from RMB 1,433,043 thousand in 2022, indicating a focus on asset management[24] - The total liabilities decreased to RMB 1,906,897 thousand from RMB 1,992,136 thousand in the previous year, reflecting improved financial health[26] - Total assets as of December 31, 2023, amounted to RMB 2,498,100 thousand, slightly up from RMB 2,435,564 thousand in 2022[35] - Cash and cash equivalents increased to RMB 523,027 thousand from RMB 497,061 thousand, indicating improved liquidity[35] - Current assets increased by approximately RMB 106.5 million from about RMB 843.0 million on December 31, 2022, to about RMB 949.5 million on December 31, 2023[192] - Current liabilities decreased by approximately RMB 1,061.3 million from about RMB 1,785.7 million on December 31, 2022, to about RMB 724.4 million on December 31, 2023[192] - The reduction in current liabilities was mainly due to a decrease in convertible bonds due within one year by RMB 1,026.4 million[192] Strategic Focus and Future Plans - The company plans to maintain a focus on capital needs while ensuring appropriate risk levels and liquidity for future growth[18] - The company is focused on expanding its hospital management services and pharmaceutical sales in the Chinese market[39] - The company aims to expand the scale of managed hospitals and improve asset quality, focusing on compliance and operational stability in 2023[130] - The company plans to continue investing in money market funds, which are deemed to be in its best interest based on business and operational needs[190] - Future strategies may include further investments in technology and operational efficiencies to manage rising costs[200] Compliance and Operational Integrity - The company has strengthened its anti-corruption framework and compliance risk management to improve operational integrity[160] - The company is closely monitoring the operational stability and cash flow of Jinhua Guangfu Hospital to ensure compliance with repayment obligations[140] - The company has implemented a unified hospital resource planning (HRP) platform to enhance operational efficiency across its hospital network[161] Hospital Development and Services - The group established a procurement center that organized 43 major procurement projects, including 26 medical device projects and 17 information system projects, collaborating with 55 suppliers[128] - The group has a total of 1,650 approved beds across five hospitals, with over 2 million outpatient visits and more than 90,000 inpatient visits in 2023[124] - The company emphasizes the development of specialty departments as a breakthrough point for high-quality growth in non-public medical institutions[126] - The company is actively participating in national initiatives to enhance medical quality and safety, aligning with the government's healthcare reform goals[94] - The company has successfully assisted hospitals in formulating medium to long-term strategic development plans and implementing management innovations[156]

編製符合國際會計準則第34號的中期財務資料時，管理層需按年度財務報表的編製基礎，對政策的 運用以及資產和負債、收入和支出的呈報金額作出判斷、估計和假設。估計的數值可能會有別於實 際結果。 香港 中環 註冊辦事處 KY1-1102, Cayman Islands 香港證券登記分處及過戶辦事處 開曼群島證券登記總處及過戶辦事處 公司網址 核數師 (i) 公平值層級－續 第一級： 在活躍市場上買賣的金融工具（如公開買賣衍生工具及股本證券）的公平值乃按 於報告期末的市場報價釐定。本集團所持有金融資產採用的市場報價為當時買 盤價。該等工具計入第一級。 (ii) 釐定公平值所用估值方法 — 就可換股債券而言－期權定價模式（例如二項模式）。 4 金融工具的公平值計量－續 下表列示截至二零二三年六月三十日止六個月第二級工具的變動。 | --- | --- | |------------------------------------------------|-------------------------| | | 可換股債券 （附註 19 ） | | | 人民幣千元 | | 於二零二三年一月一日的期初結餘 | (1,02 ...

本集團相信，在國家及各地方政府政策的持續鼓勵和支持下，社會辦醫的高質量發展環境將不斷優化。 本集團將緊跟醫藥衛生體制改革的政策要求，抓住機遇，應對挑戰，持續提升現代化管理水平，塑造品 牌影響力。 年度報告 2022 10 管理層討論及分析 二零二二年 六月二十二日 羅兵咸永道會計師事務所（「羅兵咸永道」）於其目前任期在本公司於二零二二年 六月二十二日舉行之股東週年大會（「二零二二年股東週年大會」）上屆滿後，退 任本公司核數師，乃由於本公司與羅兵咸永道不能就截至二零二二年十二月 三十一日止財政年度（「本年度」）本集團的審計費用達成共識。 在二零二二年股東週年大會上，畢馬威會計師事務所獲委任為本公司核數師， 自股東週年大會結束之時生效並直至本公司下一屆股東週年大會結束之時。 二零二二年 一九年貸款協議」），據此本公司已有條件同意向金華廣福醫院授出本金額為人 民幣80百萬元，年利率為5.23%（根據中國人民銀行不時公佈的適用基準利率進 行調整），期限自有關提款日期起計36個月的貸款（「現有二零一九年貸款」）。 有關進一步詳情，請參閱本公司日期為二零一九年七月二十四日、二零二零年 十一月二十日、二零二二年九月二十七日 ...

HOSPITAL CORPORATION 財務摘要 (1) 經調整毛利率按撇除由於收購識別出來的可辨認資產的折舊及攤銷成本影響後的年內毛利率計算。 | --- | --- | --- | --- | |--------------------------------------------------------|-------|-----------------------------|--------------------------| | | 附註 | 二零二二年 人民幣千元 | 二零二一年 人民幣千元 | | 收入 | 3 | 1,142,951 | 520,290 | | 成本 毛利 | | (992,073) 150,878 | (306,063) 214,227 | | 銷售開支 | | (344) | (2,006) | | 行政開支 | | (95,158) | (95,872) | | 金融資產減值虧損淨額 無形資產減值虧損 其他收入 | 4 | (1,867) (460,283) 5,942 | (26,477) (551,981) 7,181 | | 其他（虧損）╱收益淨額 經營虧損 ...